PICO 4 Should antiretroviral therapy (ART) be offered to HIV-infected partners in serodiscordant couples to reduce HIV transmission to uninfected partners?

Slides:



Advertisements
Similar presentations
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Advertisements

Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Male circumcision and risk of HIV infection: Current epidemiological data Helen Weiss London School of Hygiene & Tropical Medicine, UK.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Statistics for Health Care
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Investments in HIV and AIDS are paying off by reducing incidence and mortality Carlos Avila, MD, ScD. Abt Associates, Washington DC Melbourne 22 July 2014.
Unit 5: IPT Isoniazid TB Preventive Therapy
Critical Appraisal of Clinical Practice Guidelines
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
HIV status among discordant couples in sub-Saharan Africa: A meta-analysis involving more than 13,000 discordant couples Oghenowede Eyawo, 1 Damien de.
1 Potential Impact and Cost-Effectiveness of the 2009 “Rapid Advice” PMTCT Guidelines — 15 Resource-Limited Countries, 2010 Andrew F. Auld, Omotayo Bolu,
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
Multiple Choice Questions for discussion
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Reproductive Health Needs of Men and Women Enrolled in HIV Care and Treatment Services Elaine Abrams August 12, 2008 Track 1.0 Meeting.
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
Statistics for Health Care Biostatistics. Phases of a Full Clinical Trial Phase I – the trial takes place after the development of a therapy and is designed.
How to Analyze Systematic Reviews: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Country update meeting HIV Testing and Counseling and Male Circumcision.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
Hydroxyurea For the Management of Childhood SCD in Kenyan County Hospitals Hydroxyurea for SCD Panel.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
International Health Policy Program -Thailand Should Thailand adopt early initiation of ART as recommended by WHO 2010? Viroj Tangcharoensathien, Walaiporn.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Clinical Writing for Interventional Cardiologists.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.
Wipanee Phupakdi, MD September 15, Overview  Define EBM  Learn steps in EBM process  Identify parts of a well-built clinical question  Discuss.
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Anne Matthews, Health & Society, School of Nursing and Human Sciences, DCU The paradox of ‘low quality evidence; strong recommendation’: An analysis of.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
PRECONCEPTION COUNSELING AND CARE FOR HIV-INFECTED WOMEN OF CHILDBEARING AGE.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Washington D.C., USA, July 2012www.aids2012.org Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic.
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
#IAS2017 Increasing HIV test uptake & case finding through assisted HIV partner notification 25 July, 2017 Shona Dalal Department of.
Regulatory Considerations for Approval: FDA perspective
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
Module 4 (e) Pregnancy and Breast Feeding
Conflicts of interest Major role in development of GRADE
On behalf of The MTN-020/ASPIRE Study Team
The use of cotrimoxazole prophylaxis in the context of HIV infection
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
EAST GRADE course 2019 Creating Recommendations
HIV.
Undetectable = Untransmittable
Presentation transcript:

PICO 4 Should antiretroviral therapy (ART) be offered to HIV-infected partners in serodiscordant couples to reduce HIV transmission to uninfected partners? PICO 5 Should ART be started earlier than clinically indicated for the HIV-infected individuals in serodiscordant partnerships to reduce HIV transmission to uninfected partners? George W. Rutherford, M.D. Cochrane HIV/AIDS Group, University of California, San Francisco, USA WHO consultant

Searches Principal investigators of ongoing trials have been contacted Databases (01 Jan 1987 – 01 Dec 2010)  PubMed  EMBASE  Cochrane “CENTRAL”  Web of Science  LILACS  Also searched grey literature Total of records1814 Duplicates removed331 Records screened1483 Records excluded1458 Full-text articles obtained25 Studies included in review7 (PICO 4 and PICO 5)

PICO 4 framework P opulation Serodiscordant couples (heterosexual) I ntervention ART for the HIV-infected partner C omparison No ART for the HIV-infected partner O utcomes Q4: Should ART be offered to HIV-infected partners in serodiscordant couples to reduce HIV transmission to uninfected partners? 1.Incident HIV infection in the previously uninfected partner 2.Acquisition of primary drug-resistant HIV by previously HIV-uninfected partner 3.Adverse events and side effects of ART 4.HIV-related mortality 5.HIV-related morbidity 6.Quality of life (both partners)

Outcomes: PICO 4 Outcomes Relative importance ( rank 1→9 most critical) Comment HIV incidence9Critical HIV incidence (sensitivity)9Critical Acquisition of primary drug-resistant HIV by previously HIV- negative partner 9Critical Adverse events / side- effects of ART 8Critical HIV-related mortality8Critical HIV-related morbidity7Important Quality of life7Important

Summary of studies Author, yearPopulationFindings Del Romero 2010 Heterosexual couples attending a clinic in Madrid, Spain from 1989 to couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.21 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Risk ratio 0.16 (95% CI ) Incident HIV infection (index partner’s CD ) Risk ratio 0.10 (95% CI ) Incident HIV infection (index partner’s CD4 ≥350) Risk ratio 0.17 (95% CI ) Donnell 2010Heterosexual African adults who were positive for both HIV and HSV in Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia 3,408 couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.08 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Rate ratio 0.00 (95% CI ) Incident HIV infection (index partner’s CD ) Rate ratio 0.65 (95% CI ) Incident HIV infection (index partner’s CD4 ≥350) Rate ratio 0.00 (95% CI )

Summary of studies (continued) Author, yearPopulationFindings Melo 2008Heterosexual discordant couples 93 couples studied (ART) Incident HIV infection (overall) Rate ratio 0.10 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Risk ratio 0.30 (95% CI ) Incident HIV infection (index partner’s CD ) Risk ratio 0.33 (95% CI ) Musicco 1994 A cohort of heterosexual couples in Italy in which men where infected and women were uninfected 436 monogamous couples recruited from 16 centers in Italy (AZT monotherapy) AZT main exposure Incident HIV infection (overall) Rate Ratio 0.88 (95% CI ) Reynolds 2009An observational cohort of HIV discordant couples in Rakai, Uganda 193 couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.23 (95% CI )

Summary of studies (continued) Author, yearPopulationFindings Sullivan 2009 Heterosexual discordant couples in Rwanda and Zambia followed from couples studied (ART) Incident HIV infection (overall) Rate ratio 0.21 (95% CI ) Wang 2010A cohort of heterosexual couples testing and seeking treatment at county hospitals in China in 2006 to heterosexual couples studied (ART) Incident HIV infection (overall) Risk ratio 1.44 (95% CI )

GRADE evidence profile

Quality of evidence: PICO 4 Moderate quality evidence: Estimate of effect is somewhat certain Rated down for study limitations and precision issues. Rated up for strong associations. No studies explored impact of ART on many critical or important outcomes

Risk assessment: PICO 4 Del Romero 2010: Genitourinary infections occurred in 8 (5.6%) of 144 treated couples during follow up and in 62 (16.0%) of 388 untreated couples. Wang 2010: Of 1369 treated couples, 266 (19.4%) switched 259 (97.4%) of these switched due to an adverse event 3 other patients developed resistance

Risk-benefit table FactorExplanation / EvidenceJudgment Quality of Evidence Strong evidence from six of seven observational studies of a benefit There is no definitive RCT completed; a large one (HPTN052) is in the field and will be until Moderate. An estimate of effect is somewhat certain. Balance of Benefits vs. Harms There is moderate quality evidence suggests that 2-63 fewer infections would occur per 1000 couples who received ART. If two outlier studies (Musicco and Wang) are excluded (sensitivity analysis) fewer infections would occur per 1000 couples who received ART. No studies explored the impact of ART among serodiscordant couples on the following adverse outcomes: Acquisition of primary drug resistant HIV by uninfected partner Adverse events and side effects of ART HIV-related mortality HIV-related morbidity Quality of life. Benefits may outweigh harms, but rigorous RCTs and large observational studies of adverse events among serodiscordant couples are needed.

Risk-benefit table (continued) Values and preferences There is a feeling of optimism that new possibilities are emerging for HIV-positive people to live with less anxiety about infecting negative partners, and with more hope for healthy conception and childbirth options. Providers of HTC for couples must be well-informed about all of the options involving treatment for prevention so that couples can understand the implications and be free to make fully informed choices about these fundamental aspects of their lives. At the same time, care must be taken to ensure that no one is pressured to take an approach to HIV prevention that they are not comfortable with. These are personal and joint decisions. Supportive if choices are fully informed Cost and feasibility Appropriate in settings where ART is regularly provided Generally conforms to national and international guidelines Not a major issue

Proposed recommendation Statement: A ntiretroviral therapy should be offered to HIV-infected partners in serodiscordant couples to reduce HIV transmission to uninfected partners. Overall grade of recommendation: Direction: For / Against Strength: Strong / Conditional

PICO 5 framework P opulation Serodiscordant couples (where infected partner has a CD4 >350 cells) I ntervention ART for the HIV-infected partner, earlier than clinically indicated C omparison ART for the HIV-infected partner, according to existing clinical guidelines O utcomes Q5: Should ART be started earlier than clinically or immunologically indicated for the HIV-positive individuals in serodiscordant partnerships to reduce HIV transmission to HIV-negative partners? 1.Incident HIV infection in the previously uninfected partner 2.Acquisition of primary drug-resistant HIV by previously HIV- uninfected partner 3.Adverse events and side effects of ART 4.HIV-related mortality 5.HIV-related morbidity 6.Quality of life (both partners)

Outcomes: PICO 5 Outcomes Relative importance ( rank 1→9 most critical) Comment HIV incidence9Critical HIV incidence (sensitivity)9Critical Acquisition of primary drug-resistant HIV by previously uninfected partner 9Critical Adverse events / side- effects of ART 8Critical HIV-related mortality8Critical HIV-related morbidity7Important Quality of life7Important

Summary of studies Author, yearPopulationFindings Del Romero 2010 Heterosexual couples attending a clinic in Madrid, Spain from 1989 to couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.21 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Risk ratio 0.16 (95% CI ) Incident HIV infection (index partner’s CD ) Risk ratio 0.10 (95% CI ) Incident HIV infection (index partner’s CD4 > 349) Risk ratio 0.17 (95% CI ) Donnell 2010Heterosexual African adults who were positive for both HIV and HSV in Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia 3,408 couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.08 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Rate ratio 0.00 (95% CI ) Incident HIV infection (index partner’s CD ) Rate ratio 0.65 (95% CI ) Incident HIV infection (index partner’s CD4 > 349) Rate ratio 0.00 (95% CI )

Summary of Studies (continued) Author, yearPopulationFindings Melo 2008Heterosexual discordant couples 93 couples studied (ART) Incident HIV infection (overall) Rate ratio 0.10 (95% CI ) Incident HIV infection (index partner’s CD4 < 200) Risk ratio 0.30 (95% CI ) Incident HIV infection (index partner’s CD ) Risk ratio 0.33 (95% CI ) Reynolds 2009 An observational cohort of HIV discordant couples in Rakai, Uganda 193 couples analyzed (ART) Incident HIV infection (overall) Rate ratio 0.23 (95% CI ) Ongoing HPTN 052 Trial A randomized trial of ART for prevention of transmission in HIV discordant couples in Brazil, India, Malawi, Thailand, Zimbabwe Phase III, two-arm, multi-site, randomized trial of serodiscordant couples in which the index case’s CD4 is >350. Couples were randomized to receive ART at first day of enrollment or to wait for treatment initiation (couples in the second group waited until index case had two consecutive CD4 measurements in which CD4 cell count was below 250 or developed ADI).

GRADE evidence profile

Quality of evidence: PICO 5 Very low quality of evidence: Any estimate of effect is very uncertain. Rated down for study limitations, precision issues, and indirectness. Rated up for strong association. Most studies did not explore impact of ART among couples with ≥350 cells on most critical or important outcomes.

Risk assessment: PICO 5 Del Romero 2010: Genitourinary infections occurred in 8 (5.6%) of 144 treated couples during follow up and in 62 (16.0%) of 388 untreated couples.

Risk-benefit table: ≥350 CD4 cells/µL FactorExplanation / EvidenceJudgment Quality of Evidence No evidence of benefit There is no definitive RCT completed; a large one (HPTN052) is in the field and will be until Very low quality. Any estimate of effect is very uncertain. Balance of Benefits vs. Harms Very low quality evidence from two studies suggests that between 19 fewer and 35 more infections would occur per 1000 discordant couples that receive ART. There are no studies that explored the impact of ART among serodiscordant couples on the following adverse outcomes: Acquisition of primary drug resistant HIV among previously uninfected partner Adverse events and side effects of ART Earlier HIV resistance HIV-related mortality HIV-related morbidity Quality of life. No clear evidence of benefit or harm. Rigorous RCTs and large observational studies of adverse events among serodiscordant couples are needed.

Risk-benefit table (continued) Values and preferences There is a feeling of optimism that new possibilities are emerging for HIV-positive people to live with less anxiety about infecting negative partners, and with more hope for healthy conception and childbirth options. Providers of HTC for couples must be well-informed about all of the options involving treatment for prevention so that couples can understand the implications and be free to make fully informed choices about these fundamental aspects of their lives. At the same time, care must be taken to ensure that no one is pressured to take an approach to HIV prevention that they are not comfortable with. These are personal and joint decisions. Supportive if choices are fully informed Cost and feasibility Costs and ability to pay for ART when not clinically indicated will vary enormously across settings (both by economics and by HIV prevalence). This option may be particularly relevant for couples who cannot or do not want to use condoms. Cost may be a significant issue in resource- limited settings

Proposed recommendation Statement: A ntiretroviral therapy should/should not be offered to HIV-infected partners with ≥350 CD4 cells/µL who don’t meet clinical criteria for ART in serodiscordant couples to reduce HIV transmission to uninfected partners. Overall grade of recommendation: Direction: For / Against Strength: Strong / Conditional

Six-study sensitivity analysis Sensitivity analysis with all but Musicco included

Absolute risk reduction and number needed to treat by CD4 stratum CD4 stratum (cells per µL) Number of studies Incidence per 1,000 person-yearsProportion of benefit Number needed to treat Untreated couples Treated couples Absolute risk reduction < % %43.7 ≥ %52.6 Total %5.4

ART for prevention of HIV transmission, summary rate ratios by CD4 cell stratum Rutherford GW, Anglemyer A, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Databse Syst Rev 2011 (in press).